US 10,538,580 B2Granted

Anti-equol antibody composition and use therefor

AssigneeHealthcare Systems Co., Ltd.

InventorsYosuke Takimoto, Keitaro Hagiwara

Life of this patent

Estimating the term…

Loading patent…

Abstract

An anti-equol antibody composition, containing an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1′, CDR2′, and CDR3′ respectively including amino acid sequences represented by SEQ ID NO: 4-6; and an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1′, CDR2′, and CDR3′ respectively including amino acid sequences represented by SEQ ID NO: 7-9.

Claims15

Dependent claims

An anti-equol antibody composition, comprising

an anti-equol monoclonal antibody or an anti-equol monoclonal antibody fragment thereof comprising, as an immunoglobulin heavy chain variable region, a heavy chain hypervariable region CDR1 comprising the amino acid sequence represented by SEQ ID NO:
1, a hypervariable region CDR2 comprising the amino acid sequence represented by SEQ ID NO:
2 and a hypervariable region CDR3 comprising the amino acid sequence represented by SEQ ID NO:
3, and as an immunoglobulin light chain variable region, a hypervariable region CDR1′ comprising the amino acid sequence represented by SEQ ID NO:
4, a hypervariable region CDR2′ comprising the amino acid sequence represented by SEQ ID NO:
5 and a hypervariable region CDR3′ comprising the amino acid sequence represented by SEQ ID NO:
6;
and
an anti-equol monoclonal antibody or an anti-equol monoclonal antibody fragment thereof comprising, as an immunoglobulin heavy chain variable region, a heavy chain hypervariable region CDR1 comprising the amino acid sequence represented by SEQ ID NO:
1, a hypervariable region CDR2 comprising the amino acid sequence represented by SEQ ID NO:
2 and a hypervariable region CDR3 comprising the amino acid sequence represented by SEQ ID NO:
3, and as an immunoglobulin light chain variable region, a hypervariable region CDR1′ comprising the amino acid sequence represented by SEQ ID NO:
7, a hypervariable region CDR2′ comprising the amino acid sequence represented by SEQ ID NO:
8 and a hypervariable region CDR3′ comprising the amino acid sequence represented by SEQ ID NO:
9.

12 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/465,731Filed 18 Dec 2017
Priority: JP 2016-24595219 Dec 2016
Published: US 2019/0300597 A13 Oct 2019
Granted: 21 Jan 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 16/16
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from plants
C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
C12N 15/09
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or…:…
G01N 33/53
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing:…